Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 6,859 matching trials from the live ClinicalTrials.gov search.

Filters: Orlando, Florida Clear all

Conditions: Medulloblastoma
Interventions: Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate; Drug · Radiation · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Sun City, Arizona • Loma Linda, California • Orange, California + 9 more

Conditions: Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions: Esomeprazole (Nexium); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 24
States / cities: Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more

Conditions: Episodic Migraine Headache
Interventions: LBR-101 High Dose, LBR-101 Low Dose, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 63
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more

Conditions: Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions: Orbital Atherectomy, Balloon; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Pemziviptadil (PB1046); Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 26
States / cities: Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more

Conditions: Depressive Disorder, Major
Interventions: LY2216684 (edivoxetine), SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 21 more

Conditions: Autism Spectrum Disorder
Interventions: ML-004 (IR)/(ER) tablet; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 12 Years to 46 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 18
States / cities: Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more

Conditions: Generalized Anxiety Disorder
Interventions: Quetiapine Fumarate, Escitalopram oxylate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions: cabozantinib, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: Oral treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions: Defibrillator, Control; Device · Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 56
States / cities: Anchorage, Alaska • Tucson, Arizona • Glendale, California + 42 more

Conditions: Solid Tumors
Interventions: Cobimetinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Months to 30 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: Little Rock, Arkansas • Orlando, Florida • Boston, Massachusetts + 2 more

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR, Placebo; Drug
Lead sponsor: Landos Biopharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Huntsville, Alabama • Lancaster, California • Mission Viejo, California + 18 more

Conditions: Facial Wrinkles and Creases
Interventions: Autologous Human Fibroblasts (azficel-T); Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Beverly Hills, California • Santa Monica, California • Orlando, Florida + 2 more

Conditions: Multiple Sclerosis
Interventions: Quality Improvement; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Maitland, Florida • Boston, Massachusetts • Concord, New Hampshire + 1 more

Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Interventions: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 247
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: hLL1-DOX (IMMU-115); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 6
States / cities: Newark, Delaware • Orlando, Florida • Goshen, Indiana + 3 more

Conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions: Not listed
Lead sponsor: Metro Health, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 6
States / cities: Orlando, Florida • Springfield, Illinois • Wyoming, Michigan + 3 more

Conditions: Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer, Prostate Cancer
Interventions: radiation therapy, stereotactic radiosurgery; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Modesto, California + 50 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 48
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 34 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232, Cobicistat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 8 more

Conditions: Childhood Cancer
Interventions: SurvivorLink; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 15 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 9 more

Conditions: Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions: ABT-894, atomoxetine, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 22
States / cities: San Francisco, California • Wildomar, California • Orlando, Florida + 19 more

Search by objective public record fields.

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Esomeprazole for Treatment of GERD in Pediatric Patients

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

A Safety Study in Participants With Major Depressive Disorder

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases

The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

SurvivorLink: Scalability of an Electronic Personal Health Record

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)